📰 Tissue Matrix News
Page 4 - Tissue Matrix News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Tissue Matrix. Real-time updates on events, politics, business and more.
May 25, 2022
TELA Bio, Inc. (NASDAQ:TELA – Get Rating) insider Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock in a transaction that occurred on Monday, May 23rd. The shares were purchased at an average cost of $8.53 per share, for a total transaction of $42,650.00. Following the purchase, the insider now directly owns […]
May 25, 2022
TELA Bio, Inc. (NASDAQ:TELA – Get Rating) insider Ew Healthcare Partners Fund 2, bought 5,000 shares of the stock in a transaction on Friday, May 20th. The shares were acquired at an average cost of $8.79 per share, with a total value of $43,950.00. Following the purchase, the insider now owns 3,430,709 shares of the […]
May 24, 2022
TELA Bio (NASDAQ:TELA – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday, Zacks.com reports. According to Zacks, “TELA Bio Inc. is a commercial stage medical technology company. It is focused on the designing, developing and marketing of tissue reinforcement materials […]
May 20, 2022
TELA Bio, Inc. (NASDAQ:TELA – Get Rating) insider Ew Healthcare Partners Fund 2, bought 5,000 shares of the stock in a transaction on Wednesday, May 18th. The shares were bought at an average price of $8.96 per share, for a total transaction of $44,800.00. Following the acquisition, the insider now owns 3,420,709 shares in the […]
May 14, 2022
Abiomed (NASDAQ:ABMD – Get Rating) and TELA Bio (NASDAQ:TELA – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations. Risk & Volatility Abiomed has a beta of 1.34, suggesting that […]
May 9, 2022
LENSAR (NASDAQ:LNSR – Get Rating) and TELA Bio (NASDAQ:TELA – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings. Valuation & Earnings This table compares LENSAR and TELA Bio’s […]
April 12, 2022
TELA Bio (NASDAQ:TELA – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “TELA Bio Inc. is a commercial stage medical technology company. It is focused on the designing, developing and marketing of tissue reinforcement materials […]
April 7, 2022
TELA Bio, Inc. (NASDAQ:TELA – Get Rating) insider Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock in a transaction that occurred on Thursday, March 31st. The shares were purchased at an average cost of $11.54 per share, for a total transaction of $57,700.00. The transaction was disclosed in a legal filing […]
March 31, 2022
TELA Bio, Inc. (NASDAQ:TELA – Get Rating) insider Ew Healthcare Partners Fund 2, acquired 3,052 shares of TELA Bio stock in a transaction on Tuesday, March 29th. The stock was acquired at an average cost of $11.65 per share, for a total transaction of $35,555.80. The transaction was disclosed in a legal filing with the […]
March 26, 2022
TELA Bio, Inc. (NASDAQ:TELA – Get Rating) – Equities researchers at Jefferies Financial Group cut their Q1 2022 EPS estimates for TELA Bio in a report released on Monday, March 21st. Jefferies Financial Group analyst Z. Weiner now anticipates that the company will post earnings of ($0.44) per share for the quarter, down from their […]